The FDA placed a partial hold on Daiichi Sankyo and Merck’s Phase 3 study of a lung cancer drug after the companies paused enrollment for

Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.

J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.

We’re conducting a 3-minute survey that tracks the mood across the industry — science, finance, hiring and regulation

The new for-profit spinoff from the AI research group FutureHouse has raised a $70 million seed round, the latest funding behind the nascent idea of